MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
复制标题
DOI：
10.1002/ijc.25462
复制
发表时间：
2010-12-01
影响因子：
6.4
通讯作者：
Ostrand-Rosenberg, Suzanne
中科院分区：
文献类型：
--
作者：
Srivastava, Minu K.;Bosch, Jacobus J.;Wilson, Ashley L.;Edelman, Martin J.;Ostrand-Rosenberg, Suzanne
Non-small cell lung cancer (NSCLC) is the major cause of lung cancer-related deaths in the United States. We are developing cell-based vaccines as a new approach for the treatment of NSCLC. NSCLC is broadly divided into three histologic subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Since these subtypes are derived from the same progenitor cells, we hypothesized that they share common tumor antigens and vaccines that induce immune reactivity against one subtype may also induce immunity against other subtypes. Our vaccine strategy has focused on activating tumor-specific CD4+ T cells, a population of lymphocytes that facilitates the optimal activation of effector and memory cytotoxic CD8+ T cells. We now report that our NSCLC MHC II vaccines prepared from adeno, squamous, or large cell carcinomas each activate CD4+ T cells that cross-react with the other NSCLC subtypes and do not react with HLA-DR-matched normal lung fibroblasts or other HLA-DR-matched non-lung tumor cells. Using MHC II NSCLC vaccines expressing the DR1, DR4, DR7, or DR15 alleles, we also demonstrate that antigens shared among the different subtypes are presented by multiple HLA-DR alleles. Therefore, MHC II NSCLC vaccines expressing a single HLA-DR allele activate NSCLC-specific CD4+ T cells that react with the three major classes of NSCLC and the antigens recognized by the activated T cells are presented by several common HLA-DR alleles, suggesting that the MHC II NSCLC vaccines are potential immunotherapeutics for a range of NSCLC patients.
登录
查看更多内容
DOI：
10.1084/jem.188.12.2357
发表时间：
1998-12-21
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Hung K;Hayashi R;Lafond-Walker A;Lowenstein C;Pardoll D;Levitsky H
通讯作者：
Levitsky H
DOI：
10.1084/jem.181.2.619
发表时间：
1995-02-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Baskar S;Glimcher L;Nabavi N;Jones RT;Ostrand-Rosenberg S
通讯作者：
Ostrand-Rosenberg S
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
11.2
作者：
Bosch, Jacobus J.;Thompson, James A.;Ostrand-Rosenberg, Suzanne
通讯作者：
Ostrand-Rosenberg, Suzanne
影响因子：
11.2
作者：
Dissanayake, SK;Thompson, JA;Ostrand-Rosenberg, S
通讯作者：
Ostrand-Rosenberg, S